HKBN (01310) Announces Second Interim Results, Net Profit HK$317 million, Up 53% Year-on-Year
HKBN (01310) announced its second interim results for the 12 months ended August 31, 2026. The group recorded revenue of HK$11.821 billion, up 6% year-on-year; net profit of HK$317 million, up 53% year-on-year; and earnings per share of 21.4 HK cents.
HKBN (01310) Announces Second Interim Results for the 12 Months Ended August 31, 2026: Revenue HK$11.821 billion, Up 6% YoY; Net Profit HK$317 million, Up 53% YoY; Earnings Per Share 21.4 HK cents.
EBITDA was HK$2.487 billion, up 1% year-on-year, including discretionary bonuses considered for salary adjustments and enhancing employee service quality; excluding these factors, it grew 4% year-on-year.
Adjusted free cash flow increased 1% to HK$681 million, attributable to improved EBITDA and reduced bank loan interest expenses, partially offset by increased capital expenditure and working capital outflows.
Net profit grew 53% to HK$317 million. During the period, the financing structure was optimized; although one-off expenses were incurred from early repayment of bank financing, interest expenses were significantly reduced, the core business remained solid, and profitability was good.
Related Articles
.png)
DAWNRAYS PHARMA (02348) repurchased 216,000 shares on October 27 for HK$202,200.

SIMCERE PHARMA (02096) repurchased 1.042 million shares on October 27 for approximately HK$10.751 million.

JF SMARTINVEST (09636) repurchased 140,700 shares on October 27 for approximately HK$3.6401 million.
DAWNRAYS PHARMA (02348) repurchased 216,000 shares on October 27 for HK$202,200.
.png)
SIMCERE PHARMA (02096) repurchased 1.042 million shares on October 27 for approximately HK$10.751 million.

JF SMARTINVEST (09636) repurchased 140,700 shares on October 27 for approximately HK$3.6401 million.






